PEIJIA-B (09996) has successfully completed the first compassionate treatment using the TaurusTrioTM TAVR system in Hong Kong, China.

PEIJIA-B (09996) announces that the company's Board of Directors is pleased to announce that the company's product TaurusTrio, used for the treatment of symptomatic severe aortic valve regurgitation (AR), has successfully completed the first compassionate use case in Hong Kong, China. In January 2024, the company completed patient enrollment in the multicenter registered clinical trial for the TaurusTrio TAVR system in China. Follow-up assessments in the subsequent phases are currently ongoing. The company anticipates commercializing this product in China upon regulatory approval to meet the unmet needs of a large number of AR patients.